Enfortumab Vedotin Approved for Recurrent Bladder Cancer


Enfortumab vedotin-ejfv (Padcev) has been approved for people with advanced bladder cancer. FDA granted the drug accelerated approval for cancers that have progressed despite previous treatments.

Powered by WPeMatico